Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia

Kidney International

Volumn 82, Issue 11, 2012, Pages 1223-1230

  Abraham, William T ^a   Hensen, Johannes ^b   Gross, Peter A ^c   Bichet, Daniel G ^d   Josiassen, Richard C ^e   Chafekar, Deodatta S ^f   Orlandi, Cesare ^g  

^a OHIO STATE UNIVERSITY   (United States)

^b NORDSTADT HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f Shri Samarth Hospital   (India)

^g Cardiokine Biopharma   (United States)

Author keywords

clinical trial; hyponatremia; vasopressin

Indexed keywords

LIXIVAPTAN; PLACEBO; SODIUM;

ACUTE HEART FAILURE; ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; ADULT; AGED; ASTHENIA; BACKACHE; BILE DUCT CANCER; CARDIOPULMONARY INSUFFICIENCY; CHOLESTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEMYELINATION; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ELECTROCARDIOGRAM; EUVOLEMIC HYPONATREMIA; FATIGUE; FEMALE; FUNGAL MENINGITIS; HEMATOLOGICAL PARAMETERS; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; HUMERUS FRACTURE; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSMOTIC DEMYELINATION SYNDROME; OSTEOMYELITIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; SIDE EFFECT; SODIUM BLOOD LEVEL; TUMOR GROWTH; URINARY TRACT INFECTION; VITAL SIGN; VOMITING; XEROSTOMIA;

EID: 84869235804     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.275     Document Type: Conference Paper

References (32)

1. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003; 37: 1694-1702. (Pubitemid 37315112)
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119(Suppl 1): S30-S35.
3. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120: S1-S21. (Pubitemid 350027722)
4. Hoorn EJ, Rivadeneira F, van Meurs JB et al. Mild hyponatremia as a risk factor for fractures: The Rotterdam Study. J Bone Miner Res 2011; 26: 1822-1828.
5. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003; 337: 169-172. (Pubitemid 37329815)
6. Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. J Am Geriatr Soc 1995; 43: 1410-1413.
7. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112. (Pubitemid 44749318)
8. Chen LK, Lin MH, Hwang SJ et al. Hyponatremia among the institutionalized elderly in 2 long-term care facilities in Taipei. J Chin Med Assoc 2006; 69: 115-119.
9. Berl T. Treating hyponatremia: what is all the controversy about? Ann Intern Med 1990; 113: 417-419. (Pubitemid 20333447)
10. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996; 156: 1814-1820. (Pubitemid 26295226)
11. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005; 25: 240-249. (Pubitemid 41202746)
12. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994; 9: 89-91. (Pubitemid 24059127)
13. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006; 119(7 Suppl 1): S79-S82.
14. Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010; 6: 185.
15. Renneboog B, Musch W, Vandemergel X et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119: 71.e1-71.e8.
16. Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010; 19: 493-498.
17. Bissram M, Scott FD, Liu L et al. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J 2007; 37: 149-155.
18. Ayus JC, Moritz ML. Bone disease as a new complication of hyponatremia: moving beyond brain injury. Clin J Am Soc Nephrol 2010; 5: 167-168.
19. Kinsella S, Moran S, Sullivan MO et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010; 5: 275-280.
20. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005; 25: 240-249. (Pubitemid 41202746)
21. Miller M. Role of arginine vasopressin receptor antagonists in hyponatremia in the elderly. Geriatrics 2007; 62: 20-26. (Pubitemid 47196017)
22. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-865.
23. Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol 2010; 162: S13-S18.
24. Fenske W, Allolio B. The syndrome of inappropriate secretion of antidiuretic hormone: diagnostic and therapeutic advances. Horm Metab Res 2010; 42: 691-702.
25. Astellas Pharma. VAPRISOLs (Conivaptan Hydrochloride Injection) Prescribing Information. Astellas Pharma: Deerfield, IL, 2010.
26. Otsuka Pharmaceutical. SAMSCATM (Tolvaptan) Prescribing Information. Otsuka Pharmaceutical: Tokyo, Japan, 2009.
27. Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191. (Pubitemid 36042159)
28. Abraham WT, Shamshirsaz AA, McFann K et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Function Class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-1621.
29. Guyader D, Patat A, Ellis-Grosse EJ et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-1205. (Pubitemid 35253436)
30. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med 2010; 77: 715-726.
31. Abraham WT, Hensen J, Gross PA et al. Lixivaptan safety and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International 2012; e-pub ahead of print.
32. Fals-Stewart W. An interrater reliability study of the trail making test (parts A and B). Perceptual and Motor Skills 1992; 74: 39-42.